The FDA has signed off on Akari Therapeutics' endpoints for its pivotal study to assess Coversin to treat pediatric patients with hematopoietic stem cell transplant-related thrombotic microangiopathy. The trial is scheduled to launch in the last quarter of 2019.
FDA OKs Akari's Coversin study for fatal pediatric disorder
Sign up for AABB SmartBrief
News about transfusion and cellular therapies
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.